← Eichor
Condition: Stage Ii Cutaneous Melanoma Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Stage Ii Cutaneous Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
Phase N/A · 27 location(s) · Assistance Publique - Hôpitaux de Paris · NCT02828202Modified Vaccine for High Risk or Low Residual Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT01898039A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02621021Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Phase 2 · 5 location(s) · Melanoma Institute Australia · NCT06767306AMT-253 in Patients With Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Multitude Therapeutics Inc. · NCT06209580Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Phase N/A · 745 location(s) · Alliance for Clinical Trials in Oncology · NCT05334069Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Phase 1/Phase 2 · 1 location(s) · Vector Vitale LLC · NCT06506643Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Phase 2 · 1 location(s) · Dan Zandberg · NCT04114136Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Beijing Tide Pharmaceutical Co., Ltd · NCT07371663Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07215988LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Phase 2 · 14 location(s) · Canadian Cancer Trials Group · NCT06623461Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06999980COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resectio
Phase N/A · 1 location(s) · Nantes University Hospital · NCT07354152A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496A Study of GC101 TIL in Advanced Melanoma
Phase 2 · 1 location(s) · Shanghai Juncell Therapeutics · NCT06703398A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
Phase 1/Phase 2 · 15 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT07099430A Study of TRK-950 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Toray Industries, Inc · NCT05423262Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05026983Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
Phase 2 · 1 location(s) · Vastra Gotaland Region · NCT07349303Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Phase 1/Phase 2 · 6 location(s) · The Netherlands Cancer Institute · NCT06240143Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Phase 2 · 1 location(s) · Di Wu · NCT04331093A Phase II Trial of LM103 in Advanced Melanoma
Phase 2 · 13 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT07310784Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Phase 2 · 15 location(s) · IO Biotech · NCT05280314Tebentafusp-tebn With LDT in Metastatic UM
Phase 1/Phase 2 · 1 location(s) · Thomas Jefferson University · NCT06626516Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Phase 3 · 26 location(s) · Uppsala University · NCT06488482A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07136181
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.